ImmunityBio, Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
ImmunityBio announced that ANKTIVA (nogapendekin alfa inbakicept-pmln) plus BCG met its primary efficacy endpoint in the randomized QUILT-2.005 registrational trial of 370 BCG-naive non-muscle invasive bladder cancer (NMIBC) patients. The chemotherapy-free combination showed statistically significant improvement over BCG alone in carcinoma in situ patients; safety profile matched BCG alone with no treatment-related deaths. The company plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026 for this earlier-stage patient population, potentially expanding ANKTIVA's current indication (BCG-unresponsive NMIBC, approved April 2024).
Why this rating
Positive Phase 3 registration trial success in earlier-stage indication meaningfully expands addressable market; potential new indication could substantially increase ANKTIVA revenues. Material to $690M company but regulatory approval uncertain; meaningful fraction of pipeline value.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $9.00 ▲ 28.11% | at our read · unknown $7.03 | +10 min · unknown $6.71 ▼ 4.48% | +30 min · unknown $6.70 ▼ 4.67% | +1 hr · unknown $7.04 ▲ 0.14% | +4 hrs · unknown $7.20 ▲ 2.49% |
The stock had already moved -21.94% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.